Advertisement

Topics

eFFECTOR partners with Pfizer, Merck to evaluate combination of two immuno-oncology agents

05:13 EDT 21 Jun 2017 | Pharmaceutical Business Review

eFFECTOR Therapeutics has entered into a clinical collaboration and supply agreement with Pfizer and Merck to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).

Original Article: eFFECTOR partners with Pfizer, Merck to evaluate combination of two immuno-oncology agents

NEXT ARTICLE

More From BioPortfolio on "eFFECTOR partners with Pfizer, Merck to evaluate combination of two immuno-oncology agents"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...